Welcome to our dedicated page for CEL-SCI news (Ticker: CVM), a resource for investors and traders seeking the latest updates and insights on CEL-SCI stock.
CEL-SCI Corporation develops cancer immunotherapy programs centered on Multikine (Leukocyte Interleukin, Injection), an investigational neoadjuvant therapy for squamous cell carcinoma of the head and neck. Company news commonly covers Multikine regulatory interactions, FDA Orphan Drug designation for neoadjuvant use, confirmatory registration-study preparation, and the company's positioning of the therapy before surgery, radiation, and chemotherapy.
Updates also include financial results, public equity offerings used to fund Multikine development, investor presentations, and regional commercialization or regulatory-affairs agreements, including activity in Saudi Arabia. CEL-SCI's disclosures often connect clinical development with working-capital needs and potential international market access.
CEL-SCI Corporation (NYSE: CVM), a clinical stage cancer immunotherapy company, has announced plans for a proposed underwritten public offering of common stock and/or pre-funded warrants. The company intends to use the proceeds to fund the continued development of their Multikine product, along with general corporate purposes and working capital. ThinkEquity will serve as the sole book-running manager for the offering.
The securities will be offered through a shelf registration statement on Form S-3 filed with the SEC. The offering's completion, size, and terms are subject to market conditions and are not guaranteed. A preliminary prospectus supplement and base prospectus will be available through the SEC website and ThinkEquity's offices.
CEL-SCI Corporation (CVM) has completed its Breakthrough Medicine Designation application for Multikine, an immunotherapy treatment for newly diagnosed head and neck cancer, for submission to the Saudi Food and Drug Authority (SFDA). The application will be submitted by CEL-SCI's prospective Saudi partner in the coming weeks.
Key highlights:
- Multikine increased 5-year survival rates to 73% vs 45% in standard care
- 5-year death risk reduced from 55% to 27%
- SFDA typically responds within 60 days
- If approved, Multikine could be available by Summer 2025
- Head and neck cancers represent 5% of Saudi Arabia's cancer cases
CEL-SCI Corporation (CVM) reported its fiscal Q2 2025 financial results and key developments. The company plans to file for Multikine approval with Breakthrough Therapy Designation in Saudi Arabia based on Phase 3 study data. The study showed significant quality of life improvements, with 95.1% of complete responders reporting improved QoL, and complete responders achieving 100% improvement in 60% of quality of life measures.
The company is preparing to launch a 212-patient Confirmatory Registration Study for Multikine in head and neck cancer patients, concurred by the FDA. CEL-SCI is also in discussions with potential partners. Financial results showed a net loss of $6.6 million for Q2 2025, compared to $7.2 million in the prior year period, with net loss per share improving to $0.08 from $0.14.
CEL-SCI (NYSE: CVM) has announced plans to submit a regulatory filing for Multikine cancer immunotherapy in Saudi Arabia following a successful meeting with the Saudi Food and Drug Authority (SFDA). The company will seek Conditional Approval with Breakthrough Therapy designation for Multikine as a neoadjuvant treatment for newly diagnosed locally advanced head and neck cancer.
The submission will be based on data from CEL-SCI's completed 928-patient randomized controlled Phase 3 study. The SFDA's typical response time for such applications is approximately 60 days after filing. The company is exploring partnerships with local Saudi companies for commercialization, clinical trials, and manufacturing facilities to serve the Middle East and North Africa (MENA) market.
This initiative aligns with Saudi Arabia's Vision 2030 National Biotechnology Strategy, which aims to establish the Kingdom as a regional biotech hub. The MENA region faces a significant health challenge, with head and neck cancer incidence expected to double by 2030, growing at twice the projected worldwide rate.
CEL-SCI (NYSE American: CVM) has received support for its strategy to seek early approval for Multikine in head and neck cancer treatment. A new study in Cancer Cell validates that pre-surgical tumor responses lead to improved survival outcomes.
Key findings from CEL-SCI's Phase 3 trial showed that patients treated with Multikine before surgery achieved a 73% five-year survival rate compared to 45% in the control group. The study demonstrated 45 objective early responders, including 5 complete pathological responders, with a significant 306% overall survival prolongation. Responders showed a notably lower death rate of 22.2% versus 54.1% for non-responders.
The company has received FDA approval for a 212-patient Confirmatory Registration Study to verify these results. Multikine is administered as a neoadjuvant therapy immediately after diagnosis and before surgery.
CEL-SCI (NYSE: CVM) has published new data from its Phase 3 study of Multikine in the Pathology and Oncology Research journal, showing significant quality of life improvements for head and neck cancer patients.
Key findings from the study revealed that 95.1% of complete responders to Multikine reported improved quality of life, with 100% improvement in 60% of measures. Additionally, 89.4% of partial responders reported enhanced quality of life metrics.
The quality of life improvements included:
- Reduction or elimination of head and neck pain
- Enhanced ability to eat, drink, and swallow
- Improved self-care capabilities
- Better emotional wellbeing
The study, which was the largest ever conducted for newly diagnosed locally advanced head and neck cancer, demonstrated 45 objective early responders in the Multikine treated group compared to zero in the control group. Multikine is now proceeding to a final confirmatory Registration Study.